Evidence map›Paper›PMID 32077014›Full record

Observational studyAmerican journal of clinical dermatology2020

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice.

Errol P Prens, Aida M Lugo-Somolinos, Amy S Paller, Francisco Kerdel, Yinghui Duan, Henrique D Teixeira, Michelle Longcore, Alexa B Kimball

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in American journal of clinical dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. The Genetics of Hidradenitis Suppurativa.Clinical, cosmetic and investigational dermatology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Errol P PrensErasmus University Medical Center, Dr. Molewaterplein 40, Post Box 2040, Rotterdam, 3014 GD, The Netherlands. e.prens@erasmusmc.nl.ORCID http://orcid.org/0000-0002-8158-660X
Aida M Lugo-SomolinosDermatology and Skin Cancer Center, University of North Carolina Hospital, Chapel Hill, NC, USA.
Amy S PallerNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
Francisco KerdelFlorida Academic Dermatology Centers, Miami, FL, USA.
Yinghui DuanAbbVie, Inc., North Chicago, IL, USA.
Henrique D TeixeiraAbbVie, Inc., North Chicago, IL, USA.
Michelle LongcoreAbbVie, Inc., North Chicago, IL, USA.
Alexa B KimballHarvard Medical School and Beth Israel Deaconess Hospital, Boston, MA, USA.
AbbVie (United States) · USErasmus MC · NLFlorida Academic Dermatology Center · USHarvard University · USNorthwestern University · USUniversity of North Carolina Hospitals · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHidradenitis suppurativa (HS), also known as acne inversa, is a recurring, painful, chronic, and sometimes disfiguring inflammatory skin disease.

objectivesOur objective was to report the baseline clinical characteristics, natural history, and associated outcomes of patients with HS from the ongoing, prospective, non-interventional UNITE registry that is collecting data regarding the natural history and associated outcomes of HS.

methodsPatients with inflammatory HS lesions were enrolled, including adolescents (aged 12 to < 18 years) and adults (aged ≥ 18 years). None had participated in previous or current originator-adalimumab studies/registries. Patients received treatment consistent with site-specific, routine clinical practice. HS disease status was assessed by HS lesions and disease flare; treatment and outcomes data were collected at enrolment and every 6 months for ≤ 4 years.

resultsEnrolment (N = 594; 89.1% adults; 10.9% adolescents) occurred from 29 October 2013 to 29 December 2015 at 73 sites in 12 countries. At baseline, the majority were female (69.7%) and White (81.2%), had moderate-to-severe disease (Hurley stage II or III; 93.3%), and had undergone prior procedures/surgery for HS (68.7%). In total, 61.6% of adults and 49.2% of adolescents were obese; 40.2% of patients reported current tobacco use. Scarring due to lesions occurred in 91.2% of patients. The prevalence of comorbidities of interest was as follows: depression (13.3%), other psychiatric disorders (9.6%), inflammatory bowel disease (2.7%), diabetes (9.1%), and polycystic ovary syndrome (5.2%).

conclusionsIn this population from the UNITE HS registry, obesity and smoking were common, and disease burden was high, manifesting as multiple lesions, scarring, surgical history, and considerable comorbidities.

Indexed as

Cost of IllnessAdolescentAdultAgedChildCicatrixComorbidityFemaleHidradenitis SuppurativaHumansMaleMiddle AgedObesityPractice Patterns, Physicians'PrevalenceProspective Studies

Identifiers

PMID32077014
PMCPMC7371670
OpenAlexW3007799653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.